Over the past 12 months, 1 insider at Outlook Therapeutics, Inc. filed 1 open-market SEC Form 4 transaction on OTLK: 1 purchase worth $5.0M and 0 sales worth $0. Insiders have been net buyers over this period. The most recent filing was on May 28, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| May 28, 26 | Ghiath M. Sukhtian | BUY | 8.54M | $0.59 | $5.0M |
| Sep 26, 24 | Lawrence A KenyonChief Financial Officer | BUY | 5.0K | $5.69 | $28K |
| Apr 15, 24 | Syntone Ventures LlcTenPercentOwner | BUY | 714.3K | - | $0 |
| Mar 28, 24 | Yezan Munther HaddadinDirector | BUY | 1.9K | $11.82 | $22K |
| Mar 7, 24 | Jeff EvansonCHIEF COMMERCIAL OFFICER | BUY | 62.5K | $0.42 | $26K |
| Apr 20, 23 | Terry DagnonChief Operations Officer | SELL | 520.0K | $1.14 | $593K |
| Jan 20, 23 | Jeff EvansonChief Commercial Officer | SELL | 267.0K | $1.11 | $296K |
| Jan 19, 23 | Jeff EvansonChief Commercial Officer | SELL | 103.3K | $1.22 | $126K |
| Jan 18, 23 | Jeff EvansonChief Commercial Officer | SELL | 33.7K | $1.25 | $42K |
| Jan 17, 23 | Jeff EvansonChief Commercial Officer | SELL | 27.2K | $1.31 | $36K |
| Oct 7, 22 | Faisal Ghiath SukhtianDirector | BUY | 30.0K | $1.29 | $39K |
| Oct 7, 22 | Yezan Munther HaddadinDirector | BUY | 3.6K | $1.27 | $5K |
| Oct 6, 22 | Yezan Munther HaddadinDirector | BUY | 29.7K | $1.29 | $38K |
| Oct 5, 22 | Kurt J HilzingerDirector | BUY | 15.7K | $1.23 | $19K |
| Oct 4, 22 | Kurt J HilzingerDirector | BUY | 95.5K | $1.29 | $123K |
| Oct 3, 22 | Kurt J HilzingerDirector | BUY | 41.8K | $1.25 | $52K |
| Sep 30, 22 | Kurt J HilzingerDirector | BUY | 33.2K | $1.26 | $42K |
| Sep 29, 22 | Kurt J HilzingerDirector | BUY | 13.8K | $1.19 | $16K |
| Jun 21, 22 | Terry DagnonChief Operating Officer | BUY | 10.0K | $1.05 | $11K |
| Jun 21, 22 | C Russell Trenary IIICEO and President | BUY | 19.9K | $1.06 | $21K |
| Mar 1, 22 | Kurt J HilzingerDirector | BUY | 27.7K | $1.69 | $47K |
| Feb 28, 22 | Kurt J HilzingerDirector | BUY | 6.0K | $1.60 | $10K |
| Feb 24, 22 | Kurt J HilzingerDirector | BUY | 41.2K | $1.46 | $60K |
| Feb 23, 22 | Kurt J HilzingerDirector | BUY | 79.5K | $1.44 | $115K |
| Feb 22, 22 | Kurt J HilzingerDirector | BUY | 95.6K | $1.49 | $142K |
| Dec 6, 21 | Terry DagnonChief Operating Officer | BUY | 25.2K | $1.38 | $35K |
| Dec 6, 21 | C Russell Trenary IIICEO and President | BUY | 25.0K | $1.39 | $35K |
| Dec 3, 21 | Terry DagnonChief Operating Officer | BUY | 10.0K | $1.42 | $14K |
| Dec 3, 21 | Jeff EvansonChief Commercial Officer | BUY | 35.2K | $1.34 | $47K |
| Dec 2, 21 | Yezan Munther HaddadinDirector | BUY | 10.0K | $1.39 | $14K |
| Dec 2, 21 | Faisal Ghiath SukhtianDirector | BUY | 18.0K | $1.40 | $25K |
| Dec 2, 21 | C Russell Trenary IIICEO and President | BUY | 10.0K | $1.40 | $14K |
| Nov 29, 21 | Ghiath M. SukhtianDirector,TenPercentOwner | BUY | 16.00M | $1.25 | $20.0M |
Over the past 12 months, insiders at Outlook Therapeutics, Inc. filed 1 open-market purchase worth $5.0M and 0 sales worth $0 on OTLK, which makes them net buyers over the period. The most recent Form 4 was filed on May 28, 26.
The largest recent open-market OTLK insider purchase in our data was $20.0M by Ghiath M. Sukhtian, Director,TenPercentOwner, filed on Nov 29, 21.
1 different insider at Outlook Therapeutics, Inc. filed open-market SEC Form 4 transactions on OTLK over the last 12 months.
InsiderTape plots every OTLK insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every Outlook Therapeutics, Inc. insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →